| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/06/2004 | EP1000033B1 Heterocyclic derivatives which inhibit factor xa |
| 05/06/2004 | EP0999826B1 Self-emulsifying formulation for lipophilic compounds |
| 05/06/2004 | EP0980203A4 Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases |
| 05/06/2004 | EP0968182B1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 05/06/2004 | EP0963998B1 Azasteroid compound for treating or preventing prostatic cancer |
| 05/06/2004 | EP0960106B1 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands (d4) |
| 05/06/2004 | EP0959879B1 Photodynamic therapy for the treatment of osteoarthritis |
| 05/06/2004 | EP0918542B1 Use of (meth)acrylic acid copolymers to increase the permeability of mucous membranes |
| 05/06/2004 | EP0915825B1 Substituted tetrahydronaphthalene and dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
| 05/06/2004 | EP0889955B1 Recombinant phages |
| 05/06/2004 | EP0840727B1 3-hydroxy-2(1h)-pyridinone chelating agents |
| 05/06/2004 | EP0835115B1 4-(2-(n-2-carboxamidoindole)aminoethyl)-benzenesulfonamides or sulfonylureas as pdgf antagonists |
| 05/06/2004 | EP0813409B1 Treatment of cytokine growth factor caused disorders |
| 05/06/2004 | EP0812209B1 Cochleate delivery vehicles for biologically relevant molecules |
| 05/06/2004 | EP0776161B1 Use of a viral vector encoding a cytochrome p450 gene in combination with a chemotherapeutic agent for selectively destroying neoplastic cells |
| 05/06/2004 | EP0775155B1 Estra-1,3,5(10)-triene derivatives, methods of preparing such compounds and pharmaceutical compositions containing them |
| 05/06/2004 | DE10250088A1 Gegen Missbrauch gesicherte Darreichungsform Abuse-proofed dosage form |
| 05/06/2004 | DE10250087A1 Gegen Missbrauch gesicherte Darreichungsform Abuse-proofed dosage form |
| 05/06/2004 | DE10250084A1 Gegen Missbrauch gesicherte Darreichungsform Abuse-proofed dosage form |
| 05/06/2004 | DE10248601A1 Pharmazeutisches Mittel zur endonasalen Applikation bei der Behandlung von Krankheiten und Störungen des zentralen Nervensystems A pharmaceutical composition for endonasal administration in the treatment of diseases and disorders of the central nervous system |
| 05/06/2004 | DE10142665B4 C2-Disubstituierte Indan-1-one und ihre Derivate C2-Disubstituted indan-1-one and its derivatives |
| 05/06/2004 | CA2528776A1 Antifungal formulations |
| 05/06/2004 | CA2511431A1 Pharmaceutical compositions comprising flavonoids and menthol |
| 05/06/2004 | CA2503588A1 Phenethanolamine derivative for the treatment of respiratory diseases |
| 05/06/2004 | CA2503557A1 Osteogenesis promotor containing .beta.-cryptoxanthin as the active ingredient |
| 05/06/2004 | CA2503539A1 Topical skin care composition |
| 05/06/2004 | CA2503536A1 Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| 05/06/2004 | CA2503520A1 Process for producing optically active sulfoxide |
| 05/06/2004 | CA2503492A1 Implantable medical devices using zinc |
| 05/06/2004 | CA2503462A1 Selected cgrp antagonists, processes for preparing them and their use aspharmaceutical compositions |
| 05/06/2004 | CA2503391A1 Immediate release topical pharmaceutical formulation for enhancement of female sexual desire and responsiveness |
| 05/06/2004 | CA2503383A1 Extended, controlled release pharmaceutical compositions comprising charged polymers |
| 05/06/2004 | CA2503380A1 Pharmaceutical compositions containing venlafaxine |
| 05/06/2004 | CA2503373A1 Composition for enhancing physical performance |
| 05/06/2004 | CA2503284A1 Sustained release l-arginine formulations and methods of manufacture and use |
| 05/06/2004 | CA2503088A1 Therapeutic and/or preventive agent for dyschezia |
| 05/06/2004 | CA2503076A1 Novel injectable depot formulations |
| 05/06/2004 | CA2503063A1 Nitric oxide releasing selective cyclooxygenase-2 inhibitors |
| 05/06/2004 | CA2503054A1 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| 05/06/2004 | CA2502975A1 Chromones and chromone derivatives and uses thereof |
| 05/06/2004 | CA2502965A1 Dosage form that is safeguarded from abuse |
| 05/06/2004 | CA2502729A1 Use of heterocyclic amine-type compounds as neuroprotective agents |
| 05/06/2004 | CA2502696A1 Compositions and methods for treating human papillomavirus-mediated disease |
| 05/06/2004 | CA2502665A1 Substituted tetralins and indanes and their use |
| 05/06/2004 | CA2502607A1 Method for treating erectile dysfunction and increasing libido in men |
| 05/06/2004 | CA2502464A1 Substituted tetracycline compounds for the treatment of malaria |
| 05/06/2004 | CA2502433A1 Antifungal medicaments comprising arylamidine derivatives |
| 05/06/2004 | CA2502432A1 Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| 05/06/2004 | CA2502323A1 Cycloalkylamides and their therapeutic use as antiepileptic and anticonvulsant |
| 05/06/2004 | CA2502320A1 Fused cycloalkyl amides and acids and their therapeutic applications for the treatment of i.a. epilepsy |
| 05/06/2004 | CA2501781A1 Treatment of cognitive impairment using a selective dopamine d1 receptor agonist |
| 05/06/2004 | CA2501560A1 Patch and kit containing delayed-type hypersensitivity inducer |
| 05/06/2004 | CA2501228A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2 |
| 05/06/2004 | CA2500848A1 Mitotic kinesin inhibitors |
| 05/06/2004 | CA2500836A1 Metal-containing materials, compositions and methods |
| 05/06/2004 | CA2500829A1 Prophylactic treatment methods |
| 05/06/2004 | CA2500640A1 Vitamin d analogues, compositions comprising said analogues and their use |
| 05/06/2004 | CA2500090A1 Pharmaceutical product for endonasal administration for treating central nervous system diseases and disorders |
| 05/06/2004 | CA2498276A1 Depot formulations of arylheterocyclic active agents in the form of a suspension |
| 05/06/2004 | CA2493806A1 Aqueous iron carbohydrate complexes, their production and medicaments containing them |
| 05/06/2004 | CA2468903A1 Endogenous retrovirus up-regulated in prostate cancer |
| 05/05/2004 | CN1494552A Flt 4 (VEGFR-3) as target for tumor imaging and anti-tumor therapy |
| 05/05/2004 | CN1494545A 非核苷逆转录酶抑制剂 Non-nucleoside reverse transcriptase inhibitors |
| 05/05/2004 | CN1494544A Alkoxy carbonylamino heteroaryl carboxylic acid derivatives as IP antagonists |
| 05/05/2004 | CN1494543A Substituted benzofuran-2-carboxamides derivatives |
| 05/05/2004 | CN1494542A 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin II receptor antagonists |
| 05/05/2004 | CN1494541A Heterocyclic inhibitors of ERK 2 and uses thereof |
| 05/05/2004 | CN1494540A Amino alcohol derivatives |
| 05/05/2004 | CN1494539A Antagonists of MCP-1 function and methods of use thereof |
| 05/05/2004 | CN1494528A Benzophenones as inhibitors of reverse transcriptase |
| 05/05/2004 | CN1494527A Or tho-substituted and meta-substituted bis-aryl compounds, method for production thereof, their use as medicament, and pharmaceutical preparations containing there compounds |
| 05/05/2004 | CN1494526A Inhibitor of monoamine uptake |
| 05/05/2004 | CN1494435A Preparation for prophylaxis of restenosis |
| 05/05/2004 | CN1494433A Use of CD 23 antagonists for treatment of neoplastic disorders |
| 05/05/2004 | CN1494425A Carboxamide derivatives as therapeutic agents |
| 05/05/2004 | CN1494424A IL-8 receptor antagonists |
| 05/05/2004 | CN1494423A Benzimidazole derivatives as therapeutic agents |
| 05/05/2004 | CN1494422A Use of GABAA inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin E for treatment of cognitive disorders |
| 05/05/2004 | CN1494421A Highly flexible transdermal therapeutic system having nicotine as active substance |
| 05/05/2004 | CN1494420A Compounds and compositions for delivering active agents |
| 05/05/2004 | CN1494414A Pharmaceutical and cosmetic compositions for protection of skin from damages induced by sun radiations |
| 05/05/2004 | CN1493581A EB virus antisense oligomeric deoxynucleotide and its application |
| 05/05/2004 | CN1493580A Ibuprofen ribavirin ester and preparation method and use thereof |
| 05/05/2004 | CN1493579A Injection preparation of arjimycin water soluble phosphate and its preparation method |
| 05/05/2004 | CN1493578A Preparation method of golden peach glycoside and its new use in medicine |
| 05/05/2004 | CN1493571A 木犀草素金属盐及其制备方法和用途 Luteolin and its preparation method and use salt |
| 05/05/2004 | CN1493568A Roxatiding bismuth citrate and its preparation method and use |
| 05/05/2004 | CN1493357A Application of levant cotton in medicine |
| 05/05/2004 | CN1493311A 咳喘药 Cough medicine |
| 05/05/2004 | CN1493301A Application of 6-methocy bideoxy bideoxy guanosine in preparation of antihepatitis B medicine |
| 05/05/2004 | CN1493300A Argimycin oral colon orientation administration composition and use |
| 05/05/2004 | CN1493299A Application of akebia saponin D in preparation of medicine for proventing and treating osteo pathic |
| 05/05/2004 | CN1493298A Ginseng stem leaf total saponin drip pill and its preparation method |
| 05/05/2004 | CN1493297A Nebcin inhalation powder mist agent and its preparation method |
| 05/05/2004 | CN1493296A Hemsleya amabilis drip pill and its preparation method |
| 05/05/2004 | CN1493295A Oleanolic acid drip pill and its preparation method |
| 05/05/2004 | CN1493294A Diammonium glycyrrhizinate freeze dried powder ampoul agent and its preparation method |
| 05/05/2004 | CN1493293A Cefathiamidine freeze dried agent and its preparation method |
| 05/05/2004 | CN1493292A Mezloxicon liquid preparation using HPCD as solubilizing and stabilizing agent and its preparation method |
| 05/05/2004 | CN1493291A Dicyclic compound capable of inhibiting epidermis growth factor acceptor rotatory tyrosine kinase |